Related Experiment Video

Updated: May 26, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Rifaximin in the treatment of inflammatory bowel disease

Mario Guslandi

    World Journal of Gastroenterology
    |December 20, 2011
    PubMed

    Insights

    Rifaximin, an unabsorbed antibiotic, shows promise for inducing and maintaining remission in inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis with minimal side effects. Further large-scale studies are needed to confirm its efficacy and optimal dosage.

    Area of Science:

    • Gastroenterology
    • Microbiology
    • Pharmacology

    Background:

    • Inflammatory bowel diseases (IBD) involve gut microbiota-driven inflammation, making antibiotics a treatment consideration.
    • Conventional antibiotics can cause systemic side effects, particularly with long-term use.

    Discussion:

    • Rifaximin, a poorly absorbed antibiotic, offers a potential alternative with a favorable safety profile for IBD management.
    • Promising remission rates in Crohn's disease and ulcerative colitis suggest rifaximin's therapeutic potential.
    • Its role in maintaining remission for ulcerative colitis and pouchitis warrants further investigation.

    Key Insights:

    • Rifaximin demonstrates significant efficacy in inducing remission for Crohn's disease and ulcerative colitis.
    • The drug's minimal systemic absorption translates to a reduced risk of adverse effects.
    • Rifaximin may also aid in maintaining remission for specific IBD conditions.

    Outlook:

    • Larger, controlled clinical trials are essential to validate rifaximin's therapeutic benefits in IBD.
    • Further research is needed to establish the optimal dosage for different IBD patient populations.
    • Investigating rifaximin's precise mechanisms in modulating the gut microbiota in IBD is crucial.
    Keywords:
    AntibioticsGut microbiotaInflammatory bowel diseaseRifaximin

    More Related Videos

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

    Published on: December 8, 2014

    Related Concept Videos

    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

    Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
    Diagnostic studies
    A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...